Literature DB >> 27906455

Insights from the PLCO trial about prostate cancer screening.

Roman Gulati1, Peter C Albertsen2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27906455      PMCID: PMC5293617          DOI: 10.1002/cncr.30472

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  19 in total

1.  The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.

Authors:  Grace Hui-Min Wu; Anssi Auvinen; Amy Ming-Fang Yen; Matti Hakama; Teuvo L Tammela; Ulf-Håkan Stenman; Paula Kujala; Mirja Ruutu; Hsiu-Hsi Chen
Journal:  Eur Urol       Date:  2012-01-14       Impact factor: 20.096

2.  Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.

Authors:  Rebecka Arnsrud Godtman; Erik Holmberg; Hans Lilja; Johan Stranne; Jonas Hugosson
Journal:  Eur Urol       Date:  2014-12-31       Impact factor: 20.096

3.  Prostate-cancer mortality at 11 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

4.  Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.

Authors:  Roman Gulati; John L Gore; Ruth Etzioni
Journal:  Ann Intern Med       Date:  2013-02-05       Impact factor: 25.391

5.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

6.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

7.  Prostate cancer mortality in the Finnish randomized screening trial.

Authors:  Tuomas P Kilpeläinen; Teuvo L Tammela; Nea Malila; Matti Hakama; Henrikki Santti; Liisa Määttänen; Ulf-Håkan Stenman; Paula Kujala; Anssi Auvinen
Journal:  J Natl Cancer Inst       Date:  2013-03-11       Impact factor: 13.506

8.  Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.

Authors:  Paul F Pinsky; Kelly Yu; Barnett S Kramer; Amanda Black; Saundra S Buys; Edward Partridge; John Gohagan; Christine D Berg; Philip C Prorok
Journal:  Gynecol Oncol       Date:  2016-09-09       Impact factor: 5.482

9.  Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.

Authors:  Monique J Roobol; Ries Kranse; Chris H Bangma; Arno G J L H van Leenders; Bert G Blijenberg; Ron H N van Schaik; Wim J Kirkels; Suzie J Otto; Theo H van der Kwast; Harry J de Koning; Fritz H Schröder
Journal:  Eur Urol       Date:  2013-05-25       Impact factor: 20.096

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  2 in total

Review 1.  Prostate Cancer Screening.

Authors:  William J Catalona
Journal:  Med Clin North Am       Date:  2018-03       Impact factor: 5.456

2.  The presence of prostate-specific antigen checked more than 1 year before diagnostic biopsy is an independent prognostic factor in patients undergoing radical prostatectomy.

Authors:  Sung Gon Park; Kang Hee Shim; Seol Ho Choo; Se Joong Kim; Sun Il Kim
Journal:  Investig Clin Urol       Date:  2021-05-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.